CKMH Nephrology

Women's Kidney Health in Focus Time of Day as a Biological Variable in Cardiovascular and Kidney Disease Research Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter? Letter by Hu et al Regarding Article, “Cell-Specific Inducible Human APOL1 Risk Variant Expression in Mice Causes Hypertension and Renal Damage” Response by Poudel and Susztak to Letter Regarding Article, “Cell-Specific Inducible Human APOL1 Risk Variant Expression in Mice Causes Hypertension and Renal Damage” Methodologic Standards for Follow-Up Extension in Cardiovascular Trials Comprehensive Clinical Approach to Cardiovascular Kidney Metabolic Syndrome Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy Researchers at Heart uPAR/suPAR Signaling and Organ Crosstalk in Cardiovascular-Kidney-Metabolic Syndrome